Drug Trial Radar · NCT01478594
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Last checked: Nov 19, 2026Latest source record: Jul 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
265
Actual
Start
Dec 2011
Primary completion
Sep 2013
Study completion Jan 2015
Sponsor
- Lead sponsor
- AVEO Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and tolerability of tivozanib in combination with mFOLFOX6 and bevacizumab in combination with mFOLFOX6.
Conditions
- Colorectal Cancer
Interventions
TivozanibDrug
Capsules for oral administration
BevacizumabDrug
Solution for intravenous infusion
mFOLFOX6Drug
mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed Progression-Free Survival (PFS)Time frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group.
Locations
73 sites in 12 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Research Center
Gilbert, Arizona
Genesis Cancer Center
Hot Springs, Arizona
Arizona Clinical Research Center
Tucson, Arizona
University of California San Diego-Morris Cancer Center
La Jolla, California
UC Irvine Medical Center, Division of Hematology/Oncology
Orange, California
Desert Hematology Oncology Medical Group, Inc.
Rancho Mirage, California
Mountain Blue Cancer Care Center
Golden, Colorado
University of Florida, Davis Cancer Center (VA)
Gainesville, Florida
Cleveland Clinic Florida
Weston, Florida
Queen's Medical Center
Honolulu, Hawaii
University of Hawaii
Honolulu, Hawaii
Kaiser Foundation Hospitals
Honolulu, Hawaii
Northwestern University
Chicago, Illinois
Illinios Cancer Care
Peoria, Illinois
Investigative Clinical Research of Indiana, LLC
Indianapolis, Indiana
Horizon Oncology Research, Inc.
Lafayette, Indiana
Associates of Oncology Hematology, P.C.
Rockville, Maryland
University of Michigan Health
Ann Arbor, Michigan
NYU Cancer Institute
New York, New York
Alamance Regional Medical Center
Burlington, North Carolina
Tri Country Hematology / Oncology
Canton, Ohio
Signal Point Clinical Research Center, LLC
Middletown, Ohio
Cancer Care Associates
Tulsa, Oklahoma
Oregon Health and Science University
Portland, Oregon
Oncology Hematology of Lehigh Valley
Bethlehem, Pennsylvania
Northern Utah Associates
Ogden, Utah
Seattle Cancer Care Alliance
Seattle, Washington
St George Hospital
Kogarah, New South Wales, Australia
Tweed Hospital
Tweed Heads, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Ballarat Health Services
Ballarat, Victoria, Australia
Cabrini Hospital Malvern
Malvern, Victoria, Australia
Border Medical Oncology
Wodonga, Victoria, Australia
Medizinische Universitat Graz
Graz, Austria
Salzburger Landesklinken
Salzburg, Austria
Klinikum Wels-Grieskirchen GmbH
Wels, Austria
Ziekenhuisnetwerk Antwerpen - AZ Middelheim
Antwerp, Belgium
Imelda VZW
Bonheiden, Belgium
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.